Innate-like and NK Signatures in Chronic-Treated HIV Infection INSTINCT-HIV

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHospices Civils de Lyon

About this trial

Infection with the human immunodeficiency virus (HIV) is a chronic condition requiring lifelong antiretroviral therapy (ART). Despite prolonged virological control under suppressive ART, HIV persists in the form of a stable viral reservoir known as the 'integrated' reservoir, mainly localised in CD4+ memory T cells, which constitutes the obstacle to a functional or sterilising cure of the infection. The immunological mechanisms involved in the control, stability or gradual depletion of this reservoir are still not fully understood.

Among the cellular populations of the innate immune system, Natural Killer (NK) cells play an important role in the trajectory of the reservoir by having the ability to eliminate HIV-infected cells. However, several studies have shown that these NK cells exhibit variable capabilities in eliminating such cells, suggesting that inter-individual heterogeneity in innate immune responses may contribute to the observed differences in the size and persistence of the viral reservoir in people living with HIV (PLHIV) on long-term suppressive ART. Functionally, interactions between NK cell receptors and class I HLA molecules (HLA I) strongly modulate the education, repertoire and effector functions of NK cells, indicating that the immunogenetics of the host's HLA I alleles is therefore a major determinant of this variability. Certain receptor/HLA I combinations, notably receptors known as KIRs, have been associated with differences in the progression of HIV infection and immunovirological control. Consequently, their role in the dynamics of the viral reservoir during prolonged suppressive ART needs to be explored. Finally, biological sex significantly influences anti-HIV immune responses, with females showing a favourable response. Whilst sex differences in NK cell function and immune activation have been described, the impact of biological sex on the dynamics of the HIV reservoir under prolonged suppressive ART remains largely unknown and requires further investigation

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Be aged 18 or over;

Be living with HIV-1 infection;

Be under the care of the Department of Infectious and Tropical Diseases at the Lyon university Hopsital (Hospices Civils de Lyon);

Have been receiving continuous ART for at least 5 full years;

Disqualifiers

Patients who have taken part in an interventional therapeutic trial specifically targeting an HIV cure strategy likely to have a lasting effect on the immunological or virological parameters under investigation;

Patients who have experienced more than two episodes of virological rebound ≥ 100 copies/mL whilst on ART;

Pregnant women, women in labour or breastfeeding women;

Persons deprived of their liberty by judicial or administrative order;

Trial population

The target population consists of adults aged 18 years or over living with HIV who are being monitored by the Department of Infectious and Tropical Diseases at the Hospices Civils de Lyon and who have been receiving prolonged, continuous, suppressive antiviral treatment for at least five full years. Participants must meet the following criteria: * a plasma viral load that has been consistently undetectable since the start of ART and for more than 5 years; * must not have experienced, since the start of antiviral treatment, more than two isolated episodes of virological rebound ('blips') ≥ 100 copies/mL, measured in a peripheral blood sample taken during a routine consultation.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Blood test

    Biological/Vaccine

    A 50 ml venous blood sample is taken upon the participant's enrolment

Treatment groups

100 Participants
are divided into 1 treatment group
Group A: People living with HIV1 intervention

Trial outcomes

Primary outcomes

1

Identifying immune profiles associated with better control of this reservoir.

The primary endpoint is a composite measure combining the phenotypic and functional characterisation of NK cells and related cells of the innate immune system, and the number of mononuclear cells infected with HIV provirus (reservoir).

Time frame
Day 1

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: